Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 17;13(2):e13391.
doi: 10.7759/cureus.13391.

Giant Cell Arteritis and Cardiac Comorbidity

Affiliations
Review

Giant Cell Arteritis and Cardiac Comorbidity

Magela Arias et al. Cureus. .

Abstract

Giant cell arteritis (GCA) is a large vessel vasculitis with a pathogenesis that involves two CD4 T-helper cell lineages, Th1 and Th17. The goal of GCA treatment is to achieve clinical remission and prevent complications, especially vision loss. Despite recent advances in treatment and diagnostic modalities for GCA, there continues to be a gap in the medical literature in addressing treatment and follow-up for patients with GCA after clinical remission is achieved. Of the most important issues to address in this patient population by rheumatologists and primary care physicians alike, is that of cardiovascular disease (CVD) risks in GCA patients associated with the vasculitis and its mainstay of treatment with high-dose glucocorticoids over a prolonged period of time. Physicians must be aware of the CVD events that have been observed in a higher proportion compared to the general population in GCA patients, including strokes, thoracic aortic aneurysms and dissections, myocardial infarctions, and peripheral vascular disease. This review will focus on the risk of CVD in GCA patients, with recommendations for management and follow-up.

Keywords: cardiac comorbidity; giant cell arteritis; large-vessel vasculitis and gca.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Recommended treatment and follow-up for GCA.
GCA: giant cell arteritis; CVD: cardiovascular disease

Similar articles

Cited by

References

    1. Immune mechanisms in medium and large-vessel vasculitis. Weyand CM, Goronzy JJ. Nat Rev Rheumatol. 2013;9:731–740. - PMC - PubMed
    1. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Hunder GG, Bloch DA, Michel BA, et al. Arthritis Rheum. 1990;33:1122–1128. - PubMed
    1. Polymyalgia rheumatica and giant cell arteritis: a systematic review. Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. JAMA. 2016;315:2442–2458. - PubMed
    1. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Lee MS, Smith SD, Galor A, Hoffman G. Arthritis Rheum. 2006;54:3306–3309. - PubMed
    1. Survival and death causes of patients with giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study. Brekke LK, Fevang BTS, Diamantopoulos AP, Assmus J, Esperø E, Gjesdal CG. Arthritis Res Ther. 2019;21:154. - PMC - PubMed

LinkOut - more resources